We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Liquidia Technologies Announces Extension of Collaboration with PATH

News   May 22, 2013

 
Liquidia Technologies Announces Extension of Collaboration with PATH
 
 
 

RELATED ARTICLES

Shortcut to Recreating Key HIV Antibody for Vaccines

News

A portion of the roadmap toward effective neutralization of HIV has been clarified, identifying the steps that a critical HIV antibody takes to develop and maintain its ability to neutralize the virus.

READ MORE

Emerging Strategies for Treating Opioid-use Disorder

News

Anti-opioid immunopharmacotherapies (e.g., conjugate vaccines) that sequester drug peripherally, preventing opioids from reaching targeted receptors in the brain, have recently emerged as promising therapeutics.

READ MORE

Cancer Vaccine Progress: Potentially Rich Source of Tumor Specific Antigens Identified

News

The immunogenicity and efficacy of tumor specific antigen vaccination for select antigens has been validated in mouse models of cancer. The researchers believe that clinical trials for human cancer vaccines could start within the next 2-3 years.

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE